OncoMatch/Colorectal Cancer (CRC)/KRAS
Colorectal Cancer (CRC)KRAS Clinical Trials
KRAS mutations occur in approximately 45% of colorectal cancers and predict resistance to anti-EGFR therapy (cetuximab, panitumumab), which is reserved for RAS wild-type tumors. KRAS G12C-specific inhibitors including sotorasib and adagrasib have demonstrated activity in CRC. Trials explore KRAS G12C inhibitor combinations, novel inhibitors for G12D, and EGFR co-targeting to overcome adaptive resistance unique to CRC.
Top recruiting KRAS Colorectal Cancer (CRC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Amgen
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Merck Sharp & Dohme LLC
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Assistance Publique - Hôpitaux de Paris
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Centre Hospitalier Universitaire de Besancon
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy
The Netherlands Cancer Institute
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
Caigang Liu
More KRAS Colorectal Cancer (CRC) trials
See all in search →11 international trials (no US sites)
FDA-approved therapies for KRAS Colorectal Cancer (CRC)
Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.
Browse other molecular targets with active Colorectal Cancer (CRC) trials.